×
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
NASDAQ:TNDM

Tandem Diabetes Care Stock Forecast, Price & News

$60.34
-0.65 (-1.07%)
(As of 06/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$60.15
$62.09
50-Day Range
$53.22
$117.39
52-Week Range
$52.69
$155.86
Volume
744,996 shs
Average Volume
744,862 shs
Market Capitalization
$3.86 billion
P/E Ratio
754.34
Dividend Yield
N/A
Price Target
$143.00
30 days | 90 days | 365 days | Advanced Chart

Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Stock Forecast (MarketRank)

Overall MarketRank

2.60 out of 5 stars

Medical Sector

95th out of 1,433 stocks

Surgical & Medical Instruments Industry

9th out of 137 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -
Tandem Diabetes Care logo

About Tandem Diabetes Care (NASDAQ:TNDM)

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

TNDM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
Fax
N/A
Employees
2,000
Year Founded
2006

Company Calendar

Last Earnings
5/04/2022
Today
6/28/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$143.00
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$120.00
Forecasted Upside/Downside
+137.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77777777777778
Research Coverage
9 Analysts

Profitability

Net Income
$15.57 million
Pretax Margin
0.63%

Debt

Sales & Book Value

Annual Sales
$702.80 million
Cash Flow
$0.51 per share
Book Value
$6.82 per share

Miscellaneous

Free Float
62,556,000
Market Cap
$3.86 billion
Optionable
Optionable
Beta
0.69

Social Links















Tandem Diabetes Care Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care
or view top-rated stocks.

What is Tandem Diabetes Care's stock price forecast for 2022?

9 equities research analysts have issued 12 month price objectives for Tandem Diabetes Care's shares. Their TNDM stock forecasts range from $120.00 to $200.00. On average, they expect Tandem Diabetes Care's share price to reach $143.00 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care
or view top-rated stocks among Wall Street analysts.

How has Tandem Diabetes Care's stock performed in 2022?

Tandem Diabetes Care's stock was trading at $150.52 at the beginning of the year. Since then, TNDM stock has decreased by 59.9% and is now trading at $60.34.
View the best growth stocks for 2022 here
.

Are investors shorting Tandem Diabetes Care?

Tandem Diabetes Care saw a increase in short interest in June. As of June 15th, there was short interest totaling 3,900,000 shares, an increase of 18.2% from the May 31st total of 3,300,000 shares. Based on an average trading volume of 832,700 shares, the short-interest ratio is presently 4.7 days. Currently, 7.5% of the company's stock are short sold.
View Tandem Diabetes Care's Short Interest
.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Tandem Diabetes Care
.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) issued its quarterly earnings data on Wednesday, May, 4th. The medical device company reported ($0.23) earnings per share (EPS) for the quarter. The medical device company earned $175.91 million during the quarter, compared to analysts' expectations of $168.21 million. Tandem Diabetes Care had a net margin of 0.80% and a trailing twelve-month return on equity of 1.64%. The business's revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.07) EPS.
View Tandem Diabetes Care's earnings history
.

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Tandem Diabetes Care shares reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $850.00 million-$865.00 million, compared to the consensus revenue estimate of $846.54 million.

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the following people:

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.21%), Vanguard Group Inc. (9.86%), Capital World Investors (4.45%), Invesco Ltd. (3.25%), State Street Corp (2.67%) and Champlain Investment Partners LLC (2.41%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Elizabeth Anne Gasser, Howard E Greene Jr, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care
.

Which institutional investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Sei Investments Co., RTW Investments LP, UBS Group AG, Wasatch Advisors Inc., TimesSquare Capital Management LLC, Victory Capital Management Inc., and Next Century Growth Investors LLC. Company insiders that have sold Tandem Diabetes Care company stock in the last two years include Brian B Hansen, Christopher J Twomey, David B Berger, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care
or view top insider-selling stocks.

Which institutional investors are buying Tandem Diabetes Care stock?

TNDM stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Vanguard Group Inc., Invesco Ltd., Polar Asset Management Partners Inc., Atika Capital Management LLC, Bank of Montreal Can, Dimensional Fund Advisors LP, and American Century Companies Inc.. Company insiders that have bought Tandem Diabetes Care stock in the last two years include John F Sheridan, and Leigh Vosseller.
View insider buying and selling activity for Tandem Diabetes Care
or or view top insider-buying stocks.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $60.34.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $3.86 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or $0.079990 on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

Tandem Diabetes Care employs 2,000 workers across the globe.

When was Tandem Diabetes Care founded?

Tandem Diabetes Care was founded in 2006.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for Tandem Diabetes Care is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at [email protected].

This page (NASDAQ:TNDM) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.